Search Our Scientific Publications & Authors

J Stroke Cerebrovasc Dis 2021 Apr 8;30(6):105772. Epub 2021 Apr 8.

Department of Emergency Medicine, Lewis Katz School of Medicine, Temple University, 1005 Jones Hall, 1316 W. Ontario Street, Philadelphia, PA 19140, USA. Electronic address:

Objectives: There is limited knowledge of the relationship between mechanical thrombectomy (MT) and endothelial inflammation in large-vessel occlusion (LVO) acute ischemic stroke (AIS). Intimal arterial damage releases tissue factor, a precipitant of the clotting cascade and thrombosis. We report changes in blood coagulation markers after MT treated with and without tissue plasminogen activator for AIS. Read More

Rinsho Ketsueki 2021 ;62(3):186-189

Department of Pediatrics, Suikokai Munakata General Hospital.

Acquired hemophilia A (AHA) is a disease that causes severe bleeding with the appearance of an inhibitor (INH) against blood coagulation factor VIII (FVIII). The prevalence of this condition is low; it occurs in only one in one to four million people per year; however, the number of diagnosed cases has increased in recent years owing to the greater awareness of the disease. It is noteworthy that this is a hemorrhagic disease that suddenly develops in the elderly. Read More

Res Pract Thromb Haemost 2021 Feb 8;5(2):342-348. Epub 2021 Feb 8.

Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta Atlanta GA USA.

Background: The majority of patients with hemophilia A with inhibitors who undergo immune tolerance induction (ITI) achieve successful tolerance and transition to factor VIII (FVIII) prophylaxis. A portion of these patients have switched to emicizumab for bleeding prevention. However, the risk of inhibitor relapse on emicizumab is unclear. Read More

Haemophilia 2021 Mar 16. Epub 2021 Mar 16.

Israel National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel & The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel.

Introduction: BAY 94-9027 (damoctocog alfa pegol; an extended half-life PEGylated recombinant factor VIII [FVIII]) demonstrated efficacy and safety in previously treated paediatric patients (PTPs) aged <12 years with severe haemophilia A in the PROTECT VIII Kids study (NCT01775618).

Aim: To evaluate the long-term safety of BAY 94-9027 in PTPs aged <12 years at enrolment.

Methods: In the PROTECT VIII Kids study, boys <12 years with severe haemophilia A were enrolled in two age cohorts (6-<12 years and <6 years) and treated prophylactically twice weekly, every 5 days or every 7 days, with BAY 94-9027 for ≥50 exposure days (EDs). Read More

J Thromb Haemost 2021 Mar 9. Epub 2021 Mar 9.

Department of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands.

Background: Activated factor IX (FIXa) is an inefficient enzyme that needs activated factor VIII (FVIII) for full activity. Recently, we identified a network of FVIII-driven changes in FIXa employing hydrogen-deuterium eXchange mass spectrometry (HDX-MS). Some changes also occurred in active-site inhibited FIXa, but others were not cofactor-driven, in particular those within the 220-loop (in chymotrypsin numbering). Read More